May 29, 2026 12:07PM
Apr 6, 2026 01:12PM
Mar 30, 2026 08:46AM
Mar 30, 2026 08:41AM
Feb 18, 2026 07:51AM
Jan 28, 2026 06:41AM
Dec 3, 2025 06:06AM William Blair Starts Viridian Therapeutic (VRDN) at Outperform
Nov 24, 2025 07:33AM
Sep 16, 2025 05:23AM
May 20, 2025 07:01AM
May 7, 2025 04:31PM
Jan 7, 2025 08:29AM
Dec 16, 2024 07:05AM
Nov 25, 2024 05:32AM TD Cowen Starts Viridian Therapeutic (VRDN) at Buy
Sep 10, 2024 01:08PM
Sep 10, 2024 11:41AM
Sep 10, 2024 07:02AM
Aug 14, 2024 03:58PM
Jul 16, 2024 10:52AM
Jun 6, 2024 05:11AM
Jan 8, 2024 08:13AM Viridian Therapeutics (VRDN) to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
Dec 18, 2023 07:02AM
Oct 30, 2023 08:31AM
Jul 10, 2023 04:01PM
Jun 14, 2023 05:55AM
Mar 29, 2023 04:08PM
Dec 1, 2022 06:29AM
Nov 30, 2022 10:39AM 'Compelling value' in Viridian Therapeutics following Horizon Therapeutics acquisition talks
Nov 30, 2022 09:36AM
Nov 30, 2022 09:34AM
Nov 14, 2022 06:59AM
Oct 24, 2022 05:52AM
Aug 16, 2022 06:17AM
Aug 15, 2022 06:59AM
May 13, 2022 05:59AM Oppenheimer Reiterates Outperform Rating, $38 Price Target on Viridian Therapeutic (VRDN) Following the Company's Q1 Update
Jan 31, 2022 07:01AM
Jan 4, 2022 07:05AM
Nov 15, 2021 07:01AM
Oct 14, 2021 08:03AM

15,496 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All